Roche has signed a contract with Takeda subsidiary Techpool Bio that will allow the Chinese pharma company exclusively to market the Swiss firm's oral bisphosphonate drug for bone metastases Bondronat (ibandronic acid) in China. The initial deal runs to 2017, with renewal possible depending on the performance of the product.
Under the contract, Roche still owns the drug's license but will supply Bondronat manufactured in Germany to Techpool. "We believe...